In this webinar, the presenters will describe suppressive tumor immune microenvironment (TME) compartments, as well as ex vivo patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies of treatment efficacy.

Engineered humanized in vitro models and the use of human stromal and immune cells will be discussed, together with the advantages of HCI to quantify intact tumor biology.

Production Partner

Crown Bioscience

Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.

Additional Content From Crown Bioscience

Additional Content From Scientist.com

Rethink your Impurity Analysis Strategy

Rethink your Impurity Analysis Strategy

In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.

Related Content